Since the activation of ERK1/2 in general protects ovarian cancer cells from cisplatin cytotoxicity, we hypothesized that a pharmacological inhibitor (PD98059) that blocks these kinases, at the level of upstream kinases (MEK1/2), should increase the sensitivity of cells to the drug. Here, MAPK3 is linked to ovarian carcinoma.